Sorafenib, a multiple target tyrosine kinase inhibitor like ponatinib that targets PDGFR, VEGFR, and Raf kinases, is also one of the FDA-approved targeted therapies for advanced HCC for its antiproliferative and antiangiogenic effects [4]. The gene discussed is KDR; the disease is hepatocellular carcinoma.